Revenues grew 37% to £35.2mln in the six months to June 30, giving underlying earnings (EBITDA) of £6.5mln – this time last year the company was at break-even. The order backlog is up almost 27% at £118.3mln.
The group saw its cash balance grow by £700,000 to £8.1mln.
Based on foregoing figures, Ergomed said it was on track to hit full-year forecasts.
"During the first half of 2019 Ergomed has taken further significant steps to fully focus on its services business model, execute its strategy to become a leading specialised CRO [contract research] services business, and fulfil its future growth potential,” said chairman Miroslav Reljanović.
In a separate announcement, the company announced the departure of senior independent director, Peter George.